As PKC's biosensors also offer automated signal generation and high ease of use, it does away with the need to train technicians or use expensive additional equipment. The PKC test instrument requires only an initial investment, instead of the recurring investments needed by other test solutions. Overall, PKC lowers the cost of pathogen testing to almost half of that of lateral-flow technology.
"Although designed for use across a number of application areas, PKC's biosensors are used primarily in food processing," noted Dr. Thusu. "They also demonstrate high growth potential in the application areas of patient care monitoring, biodefense, environmental monitoring, and infection control. Another key application area detection of biomarkers related to all cancer types, genetic makers, DAN, RNA and CNS battery of diseases including Alzheimer's biomarkers, Parkinson and MS."
PKC's constant focus on tracking emerging customer needs enables it to introduce industry-first products and solutions designed to offer high customer value and increased return on investment (ROI). PKC is also developing biosensors using nanotechnology, including nanobiosensors, for both in-vivo and in-vitro monitoring of biomarker levels.
PKC is currently working on the first-generation nano-impedance biosensor (NIB) that exhibits the capability to detect high proteins like vascular endorphin growth factor (VEGF). This is likely to enable real-time analysis of tumors in the human body without the need for a blood draw or magnetic resonance imaging (MRI) test. Every twenty four hours, the body of each human on our planet produces one million cancer cells. Our immune system fights these cancer cells and most often wins the battle every day. Due to weakness of the immune system and reasons that are still unknown, one cancer cell from these one million cells can remain in the body. This rogue cancer cell will then start to grow and can metastasize. The science and medical community unequivocally agrees that - were we capable of detecting these metastatic cancer cells before they grow to about 1 gram in critical mass (about 1 cc in volume) - current treatment modalities could defend against the cancer and save every life. PKC VEGF NIB will give cancer patients to hopefully never experience the pain and suffering of experiencing chemotherapy, tumor resection and death. The first PKC commercial version of NIB for VEGF will be ready in about six months.Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.